APOE and Alzheimer disease: They differed in their percentages of females (70, 48, and 71%, respectively; p = 4.9 × 10−14), apolipoprotein E ε4 allele carriers (APOE-ε4, 37, 57, and 24%, respectively; p = 1.5 × 10−23) and statin-treated individuals (23 and 51% for PREVENT-AD and ADNI, respectively; p = 3.8 × 10−13, Table 1).